Cargando…

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea

INTRODUCTION: Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of coronavirus disease 2019 (COVID-19) in South Korea in 2021. The Ministry of Food and Drug Safety in South Korea mandate tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Yeon, Bu, Seon Hee, Song, EunHyang, Cho, Seongcheol, Yu, Sungbong, Kim, Jungok, Kym, Sungmin, Seo, Kwang Won, Kwon, Ki Tae, Kim, Jin Yong, Kim, Sunghyun, Ahn, Keumyoung, Jung, Nahyun, Lee, Yeonmi, Jung, Yoobin, Hwang, Chankyoung, Park, Sang Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600078/ https://www.ncbi.nlm.nih.gov/pubmed/37833467 http://dx.doi.org/10.1007/s40121-023-00859-1

Ejemplares similares

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Lee, Ji Yeon, et al.
Publicado: (2021)

Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Regdanvimab Treatment of COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
por: Kim, Taeyun, et al.
Publicado: (2022)

Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
por: Noh, Hyeong-Jun, et al.
Publicado: (2023)

Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study
por: Kim, Hyun Jin, et al.
Publicado: (2022)

Administering Antibiotics for Less Than Four Weeks Increases the Risk of Relapse in Culture-Positive Septic Arthritis of Native Joints
por: Joo, Eun-Jeong, et al.
Publicado: (2023)

Experimental and Mathematical Optimization of a Pooling Test for Detection of SARS-CoV-2 in a Population with Low Viral Load
por: Jeong, Hyeongseok, et al.
Publicado: (2021)

Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
por: Lee, Chan Mi, et al.
Publicado: (2022)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
por: Kim, Haein, et al.
Publicado: (2023)

Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Choi, Seong Jin, et al.
Publicado: (2022)

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
por: Lee, Shinwon, et al.
Publicado: (2022)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial
por: Ison, Michael G, et al.
Publicado: (2021)

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
por: Seo, Ji-Min, et al.
Publicado: (2022)

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
por: Kwak, Yee Gyung, et al.
Publicado: (2022)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
por: Chae, Ganghee, et al.
Publicado: (2022)

Improving Performance of the Human Pupil Orbit Model (HPOM) Estimation Method for Eye-Gaze Tracking
por: Lee, Seungbong, et al.
Publicado: (2022)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection
por: Choi, Young Kyun, et al.
Publicado: (2022)

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
por: Stebbing, Justin, et al.
Publicado: (2023)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Self-Assessment Questionnaire for Efficient and Safe Evaluation of Patients with Mild COVID-19
por: Jeong, Hyeongseok, et al.
Publicado: (2020)

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial
por: Maurer, Marcus, et al.
Publicado: (2022)

TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma
por: Kim, Min Soo, et al.
Publicado: (2022)

Correction to: TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma
por: Kim, Min Soo, et al.
Publicado: (2022)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
por: Marcec, Robert, et al.
Publicado: (2023)

Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
por: McSweeney, Morgan D., et al.
Publicado: (2022)

Dysregulated thrombospondin 1 and miRNA-29a-3p in severe COVID-19
por: Kim, In Soo, et al.
Publicado: (2022)

Overview of Salvia miltiorrhiza as a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action
por: Jung, Inyong, et al.
Publicado: (2020)

Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Publicado: (2023)

Suicide on YouTube:Factors engaging viewers to a selection of suicide-themed videos
por: Jung, Eun Ji, et al.
Publicado: (2021)

Colorectal cancer diagnostic model utilizing metagenomic and metabolomic data of stool microbial extracellular vesicles
por: Kim, Da Jung, et al.
Publicado: (2020)

Imaging Findings of Hepatic Paragonimiasis: A Case Report
por: Kim, Eun-A, et al.
Publicado: (2004)

Elderly Users’ Emotional and Behavioral Responses to Self-Service Technology in Fast-Food Restaurants
por: Nam, Jinyoung, et al.
Publicado: (2023)

Comparison of Ginsenoside and Phenolic Ingredient Contents in Hydroponically-cultivated Ginseng Leaves, Fruits, and Roots
por: Choi, Sang Yoon, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lp1s9sb87b8a37vih4flo9kisd